Crizotinib or alectinib are recommended as first-line treatment for ALK positive NSCLC,[13,17] while darafenib plus trametinib was recommended for BRAF V600E positive patients in the NCCN Guidelines.[13,18] Complexity of the patient’s NGS at the DNA level resulted a misjudgment and targeted BRAF V600E were prescribed firstly before target EML4-ALK; however, it provides a chance to distinguish which oncogenic signaling pathway is more important for lung cancer. This evidence concerns the gene ALK and non-small cell lung carcinoma.